Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of CorticosteroidsAsl Baakhtari S.a, e · McCombie A.b · ten Bokkel Huinink S.a, e · Irving P.g · Siegel C.A.h · Mulder R.c · Mulder C.J.e, f · Gearry R.a, d
aDepartment of Medicine, University of Otago, bDepartment of Surgery, Christchurch Hospital, cDepartment of Psychological Medicine, Christchurch Hospital, and dDepartment of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand; eDepartment of Medicine, and fDepartment of Gastroenterology, VU Medical Centre, Amsterdam, The Netherlands; gDepartment of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK; hSection of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Aim: We aimed to investigate the factors that make inflammatory bowel disease (IBD) patients more or less likely to be willing to take corticosteroids. Methods: Respondents completed a questionnaire. The primary outcome was whether the respondents would or would not use corticosteroids again to treat their IBD. Three separate univariate and multivariate analyses were performed to examine which variables predicted willingness to take steroids, including specific side effects. Results: Four hundred fifty three respondents (321 with Crohn's disease, 115 with ulcerative colitis; mean age 40 years, 297 [66%] female) completed the questionnaire. Corticosteroid efficacy (OR 6.83, 95% CI 3.67-12.7), lack of previous negative side effects (OR 0.11, 95% CI 0.04-0.32), and positive side effects (OR 2.96, 95% CI 1.63-5.40) were associated with a willingness to use corticosteroids in the future. In multivariate analysis, weight gain (OR 0.53, 95% CI 0.29-0.98) and hallucinations (OR 0.28, CI 0.09-0.89) were associated with an unwillingness to use corticosteroids again, whereas increased energy (OR 2.30, 95% CI 1.20-4.42) was the only significant positive side effect in a multivariate model. Conclusions: Past experiences with corticosteroids influence whether patients will take corticosteroids again. Clinicians should enquire about side effects and positive psychological symptoms associated with corticosteroid use.
© 2017 S. Karger AG, Basel
- Bewtra M, Johnson FR: Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient 2013;6:241-255.
- Bodger K: Cost effectiveness of treatments for inflammatory bowel disease. Pharmacoeconomics 2011;29:387-401.
- Triantafillidis JK, Merikas E, Georgopoulos F: Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 2011;5:185-210.
- Katz JA: Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am 2004;33:171-189, vii.
- Benedek TG: History of the development of corticosteroid therapy. Clin Exp Rheumatol 2011;29(5 suppl 68):S5-S12.
- Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J: The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006;24:319-330.
- Irving PM, Gearry RB, Sparrow MP, Gibson PR: Review article: appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther 2007;26:313-329.
- Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
- Kedia S, Ahuja V, Tandon R: Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol 2014;5:579-588.
- Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260.
- Buchman AL: Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289-294.
- Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J: Predictors of Crohn's disease. Gastroenterology 2006;130:650-656.
- Krupoves A, Mack DR, Seidman EG, Deslandres C, Bucionis V, Amre DK: Immediate and long-term outcomes of corticosteroid therapy in pediatric Crohn's disease patients. Inflamm Bowel Dis 2011;17:954-962.
- Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, et al: Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992;102:1647-1653.
- Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al: Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-818.
- Vermeire S, van Assche G, Rutgeerts P: Review article: Altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther 2007;25:3-12.
- Peppercorn MA: Advances in drug therapy for inflammatory bowel disease. Ann Intern Med 1990;112:50-60.
- Navarro F, Hanauer SB: Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol 2003;98(12 suppl):S18-S23.
- Harvey RF, Bradshaw JM: A simple index of Crohn's-disease activity. Lancet 1980;1:514.
- Walmsley RS, Ayres RC, Pounder RE, Allan RN: A simple clinical colitis activity index. Gut 1998;43:29-32.
IBM SPSS Statistics for Windows, ed 22.0. Armonk, IBM Corp., 2013.
- Brown ES, Chandler PA: Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry 2001;3:17-21.
- Bolanos SH, Khan DA, Hanczyc M, Bauer MS, Dhanani N, Brown ES: Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol 2004;92:500-505.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.